(Q39527656)

English

A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers

scientific article published on July 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

phase I clinical trial

0 references

author name string

Toledo H

1

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Baly A

2

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Castro O

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Resik S

4

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Laferté J

5

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Rolo F

6

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Navea L

7

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Lobaina L

8

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Cruz O

9

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Míguez J

10

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Serrano T

11

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Sierra B

12

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Pérez L

13

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Ricardo ME

14

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Dubed M

15

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Lubián AL

16

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Blanco M

17

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Millán JC

18

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Ortega A

19

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Iglesias E

20

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Pentón E

21

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Martín Z

22

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Pérez J

23

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Díaz M

24

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Duarte CA

25

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

language of work or name

0 references

publication date

1 July 2001

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

4328-4336

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Human Studies in the Development of Human Immunodeficiency Virus Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiepitope polypeptide of the HIV-1 envelope induces neutralizing monoclonal antibodies against V3 loop

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Broadly reactive antibodies against a gp120 V3 loop multi-epitope polypeptide neutralize different isolates of human immunodeficiency virus type 1 (HIV-1).

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The V3 loop based multi-epitope polypeptide TAB9 adjuvated with montanide ISA720 is highly immunogenic in nonhuman primates and induces neutralizing antibodies against five HIV-1 isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

An immunoassay with bovine serum albumin coupled peptides for the improved detection of anti V3 antibodies in HIV-1 positive human sera

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of the serologic response against two consensus V3 loop peptides from human immunodeficiency virus-1 in Cuban patients

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900111-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0264-410X(01)00111-6

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39527656&oldid=1835138772"